Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- PMID:24814090
- DOI: 10.1016/S0140-6736(14)60661-9
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Abstract
Background: Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis.
Methods: In this double-blind, placebo-controlled, randomised, phase 2 study, patients with moderately-to-severely active ulcerative colitis who had not responded to conventional therapy were recruited from 40 referral centres in 11 countries. Eligible patients (aged 18-75 years; Mayo Clinic Score [MCS] of 5 of higher [or ≥6 in USA]; and disease extending 25 cm or more from anal verge) were randomised (1:1:1) to one of two dose levels of subcutaneous etrolizumab (100 mg at weeks 0, 4, and 8, with placebo at week 2; or 420 mg loading dose [LD] at week 0 followed by 300 mg at weeks 2, 4, and 8), or matching placebo. The primary endpoint was clinical remission at week 10, defined as MCS of 2 or less (with no individual subscore of >1), analysed in the modified intention-to-treat population (mITT; all randomly assigned patients who had received at least one dose of study drug, had at least one post-baseline disease-activity assessment, and had a centrally read screening endoscopic subscore of ≥2). This study is registered with ClinicalTrials.gov, numberNCT01336465.
Findings: Between Sept 2, 2011, and July 11, 2012, 124 patients were randomly assigned, of whom five had a endoscopic subscore of 0 or 1 and were excluded from the mITT population, leaving 39 patients in the etrolizumab 100 mg group, 39 in the etrolizumab 300 mg plus LD group, and 41 in the placebo group for the primary analyses. No patients in the placebo group had clinical remission at week 10, compared with eight (21% [95% CI 7-36]) patients in the etrolizumab 100 mg group (p=0·0040) and four (10% [0·2-24]) patients in the 300 mg plus LD group (p=0·048). Adverse events occurred in 25 (61%) of 41 patients in the etrolizumab 100 mg group (five [12%] of which were regarded as serious), 19 (48%) of 40 patients in the etrolizumab 300 mg plus LD group (two [5%] serious), and 31 (72%) of 43 patients in the placebo group (five [12%] serious).
Interpretation: Etrolizumab was more likely to lead to clinical remission at week 10 than was placebo. Therefore, blockade of both α4β7 and αEβ7 might provide a unique therapeutic approach for the treatment of ulcerative colitis, and phase 3 studies have been planned.
Funding: Genentech.
Copyright © 2014 Vermeire et al. Open Access article distributed under the terms of CC BY-NC-ND. Published by Elsevier Ltd. All rights reserved.
Comment in
- Etrolizumab in moderate-to-severe ulcerative colitis.Armuzzi A, Felice C.Armuzzi A, et al.Lancet. 2014 Jul 26;384(9940):285-6. doi: 10.1016/S0140-6736(14)60529-8. Epub 2014 May 9.Lancet. 2014.PMID:24814088No abstract available.
- Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa.Fiorino G, Danese S.Fiorino G, et al.Gastroenterology. 2014 Dec;147(6):1433-5. doi: 10.1053/j.gastro.2014.10.018.Gastroenterology. 2014.PMID:25457851No abstract available.
Similar articles
- Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group.Peyrin-Biroulet L, et al.Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.Lancet Gastroenterol Hepatol. 2022.PMID:34798039Clinical Trial.
- Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group.Vermeire S, et al.Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17.Lancet Gastroenterol Hepatol. 2022.PMID:34798037Clinical Trial.
- Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group.Rubin DT, et al.Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17.Lancet Gastroenterol Hepatol. 2022.PMID:34798036Clinical Trial.
- Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?D'Amico F, Danese S, Peyrin-Biroulet L.D'Amico F, et al.Expert Opin Biol Ther. 2020 Apr;20(4):353-361. doi: 10.1080/14712598.2020.1717465. Epub 2020 Jan 21.Expert Opin Biol Ther. 2020.PMID:31951748Review.
- Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM.Tang MT, et al.Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. doi: 10.1111/apt.14631. Epub 2018 Mar 30.Aliment Pharmacol Ther. 2018.PMID:29601644Free PMC article.Review.
Cited by
- Novel Therapies for Eosinophilic Disorders.Bochner BS.Bochner BS.Immunol Allergy Clin North Am. 2015 Aug;35(3):577-98. doi: 10.1016/j.iac.2015.05.007.Immunol Allergy Clin North Am. 2015.PMID:26209901Free PMC article.Review.
- Next-Generation Therapeutics for Inflammatory Bowel Disease.Dulai PS, Sandborn WJ.Dulai PS, et al.Curr Gastroenterol Rep. 2016 Sep;18(9):51. doi: 10.1007/s11894-016-0522-0.Curr Gastroenterol Rep. 2016.PMID:27461274Free PMC article.Review.
- The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.Fiorino G, Gilardi D, Danese S.Fiorino G, et al.Therap Adv Gastroenterol. 2016 Jul;9(4):503-12. doi: 10.1177/1756283X16647935. Epub 2016 May 19.Therap Adv Gastroenterol. 2016.PMID:27366219Free PMC article.Review.
- The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment.Lamb CA, Mansfield JC, Kirby JA, Keir ME.Lamb CA, et al.J Crohns Colitis. 2019 Jul 25;13(7):956-957. doi: 10.1093/ecco-jcc/jjy219.J Crohns Colitis. 2019.PMID:30596983Free PMC article.No abstract available.
- β7 Gives Tregs a Gut Area Code.Liu CY.Liu CY.Cell Mol Gastroenterol Hepatol. 2020;9(3):543-544. doi: 10.1016/j.jcmgh.2019.11.010. Epub 2019 Dec 10.Cell Mol Gastroenterol Hepatol. 2020.PMID:31835017Free PMC article.No abstract available.
Publication types
MeSH terms
Substances
Associated data
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials